Literature DB >> 19392638

Current and future therapies for age-related macular degeneration.

Julia Beutel1, Martin Rudolf, Salvatore Grisanti.   

Abstract

BACKGROUND: Age-related macular degeneration is the leading cause of blindness, with an increasing incidence as the elderly population expands.
OBJECTIVE: In this article we review current therapeutic strategies and discuss possible future targets.
METHODS: A review of the literature and ongoing clinical trials was undertaken.
RESULTS: Currently, established therapies for neovascular AMD-like photodynamic therapy and anti-VEGF therapies allow stabilization or even improvement of vision. Potential future drugs under development for advanced AMD or its prevention target the signal transduction cascade of different angiogenic molecules. These drugs intervene at different levels of the involved processes including the RNA production and specific protein expression as well as inflammatory, apoptotic, or metabolic processes.
CONCLUSION: Combining different strategies targeting angiogenesis, inflammation and apoptosis, or interfering early in--or even prior to--the formation of choroidal neovascularization, may improve the future management of age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19392638     DOI: 10.1517/14728210902824141

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  4 in total

1.  Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study.

Authors:  Salomon-Yves Cohen; Eric H Souied; Michel Weber; Gérard Dupeyron; Gérard de Pouvourville; Michel Lievre; Anne Ponthieux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-11-06       Impact factor: 3.117

2.  High-resolution contrast-enhanced optical coherence tomography in mice retinae.

Authors:  Debasish Sen; Elliott D SoRelle; Orly Liba; Roopa Dalal; Yannis M Paulus; Tae-Wan Kim; Darius M Moshfeghi; Adam de la Zerda
Journal:  J Biomed Opt       Date:  2016-06-01       Impact factor: 3.170

3.  New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration.

Authors:  Young Gun Park; Hyun Wook Rhu; Seungbum Kang; Young Jung Roh
Journal:  J Ophthalmol       Date:  2012-02-09       Impact factor: 1.909

4.  Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources.

Authors:  Vincent Daien; Bora M Eldem; James S Talks; Jean-Francois Korobelnik; Paul Mitchell; Robert P Finger; Taiji Sakamoto; Tien Yin Wong; Obaro Evuarherhe; Gemma Carter; Joao Carrasco
Journal:  BMC Ophthalmol       Date:  2019-10-16       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.